Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
Scilex Holding Is Maintained at Buy by HC Wainwright & Co.
Dow Jones16:07 ET
Express News | HC Wainwright & Co. Maintains Buy on Scilex Holding, Lowers Price Target to $8
Benzinga15:57 ET
Scilex Holding Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/03/2024 831.15% HC Wainwright & Co. $12 → $8 Maintains Buy 12/04/2023 1296.73% HC Wainwright & Co. → $1
Benzinga15:55 ET
Express News | Scilex Holding Company : H.c. Wainwright Cuts Target Price to $8 From $12
ReutersMay 3 06:17 ET
Express News | Scilex Holding Company Announces Closing of $15 Million Registered Direct Offering
ReutersApr 25 16:01 ET
Express News | Scilex Holding Company Announces $15M Registered Direct Offering Of 15M Shares At $1.00/Share
Moomoo 24/7Apr 24 08:02 ET
Express News | Scilex Holding Company Announces $15 Million Registered Direct Offering
Moomoo 24/7Apr 24 08:00 ET
Scilex Issues Preliminary Q1 Sales Results for ZTlido
Scilex Holding (SCLX) said Tuesday that Q1 net sales of ZTlido are expected to be between $12 million and $13 million, compared with $10.6 million in Q1 2023. The company also said that it plans to re
MT NewswiresApr 16 14:09 ET
Scilex to Reduce R&D Expenses in 2024, Comments on Actions Post Change Healthcare Cyberattack
Seeking AlphaApr 16 09:14 ET
Express News | Scilex Holding Co - Plans to Reduce R&D and Other Administrative Expenses and to Focus on Its Late-Stage Pipeline Programs Such as SP-102
Moomoo 24/7Apr 16 09:04 ET
Express News | Scilex Holding Co Sees Ztlido Net Sales for Q1 of 2024 in Range of $12.0 Mln to $13.0 Mln
Moomoo 24/7Apr 16 09:04 ET
Express News | Scilex Holding Launches Co-Pay Programs For ZTlido And ELYXYB For Commercially Insured Patients And Addition Of ELYXYB To Multi-State Medicaid Pharmaceutical Purchasing Group To Purchasing Pool
Moomoo 24/7Apr 9 09:10 ET
Scilex Holding Company Announces Launching of Co-Pay Programs for Both ZTlido and ELYXYB for Commercially Insured Patients and the Addition of ELYXYB to a Multi-State Medicaid Pharmaceutical Purchasing Group to Its Purchasing Pool
Scilex Holding Company (Nasdaq: SCLX)today announced launching of co-pay programs for both ZTlido and ELYXYB with the out-of-pocket costs for its product portfolio for commercially insured patients capped at $25 monthly, with certain eligible patients paying as low as $0.
GlobeNewswireApr 9 09:00 ET
Express News | U.S. Bankruptcy Court Extends Lockup Period On Shares Of Scilex Stock Distributed By Sorrento To Its Stockholders As Dividend
Moomoo 24/7Mar 27 09:01 ET
Scilex Holding Ends Equity Purchase Deal With Yorkville
TipRanksMar 25 14:02 ET
Express News | Scilex Holding Co And Ya II PN Mutually Agreed To Terminate Amended And Restated Standby Equity Purchase Agreement, Dated As Of Feb 8, 2023
Moomoo 24/7Mar 25 13:49 ET
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
Scilex has been working with its co-pay savings card adjudicators to resolve the recent breakdown of processing of insurance claims by Change Healthcare, following a cyber-attack on Change Healthcare.
GlobeNewswireMar 21 09:30 ET
Scilex Seeks FDA Approval to Add Dosing Guidance to Gout Treatment Drug Label
Scilex Holding (SCLX) said Wednesday it plans to seek approval from the US Food and Drug Administration to change the label of gout drug Gloperba to add dosing guidance for people with renal impairmen
MT NewswiresMar 20 12:07 ET
Scilex Holding To Seek Approval Fro MFDA For Modification Of Gloperba To Include
Scilex Holding Company (NASDAQ:SCLX, "Scilex" or "Company"))))), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for t
BenzingaMar 20 11:02 ET
Scilex Holding Company Announces Seeking Approval From the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients With Renal Impairment and Other Circumstances Where Dose Adjustment Is Needed
Scilex Holding Company (Nasdaq: SCLX)today announced it will seek approval from the FDA for the modification of the Gloperba label to include its ability to utilize dosing flexibility of liquid formulation.
GlobeNewswireMar 20 11:00 ET
No Data
No Data